bioAffinity Technologies enters $5.8M ATM equity sales agreement with WallachBeth Capital

bioAffinity Technologies, Inc.

Entered ATM agreement with WallachBeth Capital to sell up to $5,801,000 of common stock.
WallachBeth will receive 3.0% commission on gross proceeds of shares sold.
Company sets parameters for sales; no obligation to sell any shares.
Agreement can be terminated on 10 days' notice by either party.
Shares offered under existing S-3 shelf registration statement.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.